# An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

> **NCT01712347** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 351 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT01712347
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-11
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-07-01
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712347, "An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01712347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*